Vertex Pharmaceuticals (VRTX) Other financing activities (2012 - 2026)

Vertex Pharmaceuticals' Other financing activities history runs 15 years deep, the most recent figure standing at -$400000.0 for Q1 2026.

• In Q1 2026, Other financing activities rose 20.0% year-over-year to -$400000.0; the TTM figure through Mar 2026 stood at $3.8 million (up 72.73% YoY), while the FY2025 annual figure was $3.7 million, down 40.32% from the prior year.
• Other financing activities was -$400000.0 for Q1 2026 at Vertex Pharmaceuticals, down from $1.1 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $3.5 million in Q1 2024 to a low of -$1.5 million in Q4 2023.
• Historically, Other financing activities has averaged $870588.2 across 5 years, with a median of $1.1 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Other financing activities plunged 236.36% in 2023, then soared 218.18% in 2024.
• A 5-year view of Other financing activities shows it stood at $1.1 million in 2022, then slumped by 236.36% to -$1.5 million in 2023, then surged by 160.0% to $900000.0 in 2024, then grew by 22.22% to $1.1 million in 2025, then slumped by 136.36% to -$400000.0 in 2026.
• The last three Other financing activities figures came in at -$400000.0 (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.